Solesence (SLSN)
NASDAQ:SLSN
Want to see SLSN full AI Analyst Report?
SLSN Stock Chart & Stats
$2.17
--
Market closed
$2.17
--
Day’s Range― - ―
52-Week Range$0.78 - $5.63
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.43K
Market Cap
$96.06M
Enterprise Value$117.77M
Total Cash (Recent Filing)$573.00K
Total Debt (Recent Filing)$22.28M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding70,632,450
10 Day Avg. Volume39,901
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)6.38
Price to Sales (P/S)1.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda65.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Product LaunchesTwo new proprietary technologies (Chromalum, WHSPR) broaden Solesence's product set into SPF-infused hybrids and hair/scalp adjacencies. These offerings strengthen technical differentiation, support deeper B2B customer integrations, and can create durable pricing and share gains across cosmetics verticals.
Forward Order BookA $47M shipped + open orders backlog provides meaningful near- to medium-term revenue visibility, helps stabilize manufacturing utilization, and supports predictable cash conversion as orders convert. This backlog reduces immediate top-line volatility and underpins execution of strategic efficiency initiatives.
Margin Improvement TargetsManagement has delivered a 300bp gross margin uplift to 26% and reiterated a 30% gross margin floor plus a path back to double-digit EBITDA. Combined with operational actions (SIOP, consolidation, labor efficiency), this signals credible structural margin improvement if execution continues, improving long-term cash generation.
Bears Say
Weak Cash GenerationVery weak and volatile cash generation (near-zero operating cash, materially negative FCF) limits Solesence's ability to self-fund investment, absorb shocks, or accelerate growth without external capital. Persistent FCF deficits raise refinancing and liquidity risk over the medium term.
Compressed ProfitabilityYear-over-year margin compression and modest top-line decline erode the company's earnings resilience. Lower margins reduce reinvestment capacity and increase sensitivity to cost inflation or demand softness, making achievement of stated margin targets and durable profits more challenging.
Elevated LeverageAlthough leverage has materially improved, a ~1.3x debt-to-equity for a consumer-facing specialty-chemicals firm still leaves limited balance-sheet cushion. Elevated leverage combined with weak cash flow constrains strategic flexibility and raises risk during operational setbacks or prolonged margin recovery periods.
Solesence News
SLSN FAQ
What was Solesence’s price range in the past 12 months?
Solesence lowest stock price was $0.78 and its highest was $5.63 in the past 12 months.
What is Solesence’s market cap?
Solesence’s market cap is $96.06M.
When is Solesence’s upcoming earnings report date?
Solesence’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were Solesence’s earnings last quarter?
Currently, no data Available
Is Solesence overvalued?
According to Wall Street analysts Solesence’s price is currently Overvalued.
Does Solesence pay dividends?
Solesence does not currently pay dividends.
What is Solesence’s EPS estimate?
Solesence’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solesence have?
Solesence has 70,632,450 shares outstanding.
What happened to Solesence’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Solesence?
Currently, no hedge funds are holding shares in SLSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solesence Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
10.50%
Trailing 12-Months
Asset Growth
0.11%
Trailing 12-Months
Company Description
Solesence
Solesence (SLSN) is a biotechnology company focused on developing innovative solutions for the cosmetics and personal care industries. The company specializes in harnessing the power of natural ingredients to create advanced formulations that enhance the performance and sensory attributes of beauty products. With a strong emphasis on sustainability and efficacy, Solesence serves a diverse range of clients, including leading beauty brands and manufacturers, by providing proprietary technology and products that improve product stability, texture, and delivery of active ingredients.
SLSN Company Deck
SLSN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: near-term financial results were pressured by shipment delays and investments tied to the Transform and Transcend initiative (revenue down ~11%, net loss and negative adjusted EBITDA), but key positives include a 300-basis-point gross margin improvement to 26%, a $47M shipped + open orders book, new proprietary technology launches (Chromalum and WHSPR), completed co-marketing activations with brand partners, and a clear operational roadmap (SIOP, shift changes, facility consolidation) with reiterated guidance including a 30% gross profit floor and a plan to return to double-digit EBITDA margins by year-end. Given the balance of material execution risks and encouraging operational and commercial progress, the tone is cautiously optimistic but transitional.View all SLSN earnings summariesTechnical Analysis
Ownership Overview
76.99% Insiders
2.00% Mutual Funds
0.05% Other Institutional Investors
18.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---